ServicenavigationHauptnavigationTrailKarteikarten


Forschungsstelle
INNOSUISSE
Projektnummer
10278.1;9 PFDP-LS
Projekttitel
Synthetic Virus-Like Particles (SVLPs): A new Approach to Synthetic Vaccines and Nanomedicine
Projekttitel Englisch
Synthetic Virus-Like Particles (SVLPs): A new Approach to Synthetic Vaccines and Nanomedicine

Texte zu diesem Projekt

 DeutschFranzösischItalienischEnglisch
Kurzbeschreibung
Anzeigen
-
-
Anzeigen
Abstract
Anzeigen
-
-
Anzeigen

Erfasste Texte


KategorieText
Kurzbeschreibung
(Deutsch)
Synthetic Virus-Like Particles (SVLPs): A new Approach to Synthetic Vaccines and Nanomedicine
Kurzbeschreibung
(Englisch)
Synthetic Virus-Like Particles (SVLPs): A new Approach to Synthetic Vaccines and Nanomedicine
Abstract
(Deutsch)
This Discovery grant should support the launch of the start-up (spin-out) company Virometix AG. The company will exploit a fundamentally new approach for the rational design and production of immuno-therapeutic drugs and vaccines using the tools of chemistry. The so-called SVLP technology provides a breakthrough in the creation of nanoscale biological assemblies for multivalent display of epitope mimetics. A new generation of synthetic vaccines will be developed using this technology to combat infectious and chronic human diseases. The technology is based on the use of virus-like particles made using artificial, fully synthetic building blocks, to deliver target antigens to cells in the immune system.
Abstract
(Englisch)
This Discovery grant should support the launch of the start-up (spin-out) company Virometix AG. The company will exploit a fundamentally new approach for the rational design and production of immuno-therapeutic drugs and vaccines using the tools of chemistry. The so-called SVLP technology provides a breakthrough in the creation of nanoscale biological assemblies for multivalent display of epitope mimetics. A new generation of synthetic vaccines will be developed using this technology to combat infectious and chronic human diseases. The technology is based on the use of virus-like particles made using artificial, fully synthetic building blocks, to deliver target antigens to cells in the immune system.